Please try another search
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services. Jinling Pharmaceutical Company Limited was founded in 1998 and is headquartered in Nanjing, China.
Name | Age | Since | Title |
---|---|---|---|
Yajun Chen | 54 | - | Vice Chairman & President |
Sheng Chen | 53 | 2017 | VP & Non-Independent Director |
Yang Wang | 44 | 2023 | VP, Chief Accountant & Non-Independent Director |
Jian Wang | 50 | 2019 | VP & Non-Independent Director |
Hongqin Li | 54 | 2017 | Chairman of the Supervisory Board |
Yongjian Shen | 44 | 2020 | Independent Director |
Yanping Gao | 59 | 2020 | Independent Director |
Hai Chen | - | 2023 | Non-Independent Director |
Hai Chen | 43 | 2023 | President, Board Secretary & Non-Independent Director |
Qunhong Zhang | - | 2023 | Non-Independent Director |
Jian Huang | 53 | - | Employee Supervisor |
Xiaoqiang Cao | - | 2023 | Non-independent Director |
Junping Kou | - | 2023 | Independent Director |
Weijie Ye | 41 | 2020 | Non-Employee Supervisor |
Guangyu Yan | 44 | 2020 | Non-Employee Supervisor |
Yusheng Zhou | - | 2023 | Non-Employee Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review